"Timidylate Synthase" is known as the expression of the TYMS gene located in the short arm, becoming a homodimeric methyltransferase enzyme, which significantly aids in the repair of DNA in humans. However, there are social niches, where despite having a genetic structure and similarities under the socio-demographics of its inhabitants, can generate alterations during its construction and make these, another new factor common or deeply differentiating, is acquired progressively, as part of biological processes. This is known as polymorphisms, where there is a variation in the chromosomes that make up the sequence of a specific place in the DNA.
In 2017, a group of researchers, Venezuelans, consisting of Cecilia Villegas, Carlos Flores-Angulo, Jose A. Martinez, Flor Herrera and Nancy Moreno, conducted a field study, where they sought to explain, determine and understand the TYMS gene and its behavior Within a society like Venezuela, which has cancer as the second reason for death referring to health states.
Supported by the University of Carabobo, in the state of Aragua, the research resulted in the fact that TYMS polymorphisms do have an impact on the prognosis and development of some types of cancer in Venezuela. The study was based on everything related to thymidylate synthase (TS), which is one of the main objectives of anti-cancer treatments such as chemotherapy; being encoded in turn by the TYMS gene. The reaction presented a significant variation depending on whether the person was important in TS levels, in response to the functional genetic polymorphisms in the TYMS gene.
The process consisted of a sample population of 260 adult volunteers, of which 116 were men and 144 women, all with something in common: They were not from Venezuela but through the predictions of their TS expression based on Haplotypes 5 '. UTR / 3'UTR within the Venezuelan central territory could give phenotypic results.
The genetic component that prevails in the mixed population of this region is Spanish (0.604 ± 18) followed by Amerindian (0.235 ± 5) and African (0.161 ± 22) components. Giving as a final result that at least 50.77% of the individuals were associated with poor response to treatment with 5-FU. However, these data cannot be extrapolated because the genotype distributions vary depending on the populations, as well as the drugs, so that there is still a need to carry out biomarker studies of Pharmacogenetics. to be able to bridle and greater and better control in places such as Latin America, where there is a predominance of miscegenation.
Read the full investigation: